JP2014514308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514308A5 JP2014514308A5 JP2014505381A JP2014505381A JP2014514308A5 JP 2014514308 A5 JP2014514308 A5 JP 2014514308A5 JP 2014505381 A JP2014505381 A JP 2014505381A JP 2014505381 A JP2014505381 A JP 2014505381A JP 2014514308 A5 JP2014514308 A5 JP 2014514308A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- alkynyl
- alkenyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 53
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 41
- 229910052799 carbon Inorganic materials 0.000 claims description 40
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 229910052717 sulfur Inorganic materials 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 31
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 29
- 150000001721 carbon Chemical group 0.000 claims description 28
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 24
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims description 24
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 24
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 18
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
- 125000006736 (C6-C20) aryl group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
- 229940035893 uracil Drugs 0.000 claims description 12
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 11
- 229940104302 cytosine Drugs 0.000 claims description 10
- 239000002777 nucleoside Substances 0.000 claims description 10
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- -1 R 8 is H Chemical group 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 5
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 5
- 229940122806 Cyclophilin inhibitor Drugs 0.000 claims description 5
- 241000711549 Hepacivirus C Species 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical class N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 5
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims description 5
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- DKSVBVKHUICELN-UHFFFAOYSA-N 3-ethoxy-6-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]-1,2-benzoxazole Chemical compound C=1C=C2C(OCC)=NOC2=CC=1OCCC(CC1)CCN1C1=CC=C(C)N=N1 DKSVBVKHUICELN-UHFFFAOYSA-N 0.000 claims description 4
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 229940125400 channel inhibitor Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 claims description 4
- 229960000471 pleconaril Drugs 0.000 claims description 4
- 239000002911 sialidase inhibitor Substances 0.000 claims description 4
- 229940113082 thymine Drugs 0.000 claims description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 3
- 241000725619 Dengue virus Species 0.000 claims description 3
- 241000710781 Flaviviridae Species 0.000 claims description 3
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 3
- 241000710912 Kunjin virus Species 0.000 claims description 3
- 241000710908 Murray Valley encephalitis virus Species 0.000 claims description 3
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 3
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 3
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 3
- 241000710886 West Nile virus Species 0.000 claims description 3
- 241000710772 Yellow fever virus Species 0.000 claims description 3
- 208000020329 Zika virus infectious disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 229940051021 yellow-fever virus Drugs 0.000 claims description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 claims description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims description 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229950004244 laninamivir Drugs 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 2
- 229960001084 peramivir Drugs 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 241000124008 Mammalia Species 0.000 description 3
- 229910019946 S-S Inorganic materials 0.000 description 3
- 229910019939 S—S Inorganic materials 0.000 description 3
- 241000711557 Hepacivirus Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474848P | 2011-04-13 | 2011-04-13 | |
| US61/474,848 | 2011-04-13 | ||
| PCT/US2012/033675 WO2012142523A2 (en) | 2011-04-13 | 2012-04-13 | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514308A JP2014514308A (ja) | 2014-06-19 |
| JP2014514308A5 true JP2014514308A5 (enExample) | 2015-05-28 |
| JP6043338B2 JP6043338B2 (ja) | 2016-12-14 |
Family
ID=46001834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505381A Expired - Fee Related JP6043338B2 (ja) | 2011-04-13 | 2012-04-13 | 抗ウイルス治療用の１’−置換ピリミジンｎ−ヌクレオシド類似体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8877733B2 (enExample) |
| EP (1) | EP2697241B1 (enExample) |
| JP (1) | JP6043338B2 (enExample) |
| KR (1) | KR20140019832A (enExample) |
| CN (1) | CN103476783A (enExample) |
| AU (1) | AU2012242517B2 (enExample) |
| BR (1) | BR112013026219A2 (enExample) |
| CA (1) | CA2830689A1 (enExample) |
| EA (1) | EA201391264A1 (enExample) |
| ES (1) | ES2744587T3 (enExample) |
| IL (1) | IL228680A0 (enExample) |
| MX (1) | MX2013011915A (enExample) |
| WO (1) | WO2012142523A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PY0111577A (es) | 2000-05-23 | 2017-01-02 | Idenix Cayman Ltd | Métodos y composiciones para el tratamiento del virus de la hepatitis c |
| RU2005118421A (ru) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-разветвленные нуклеозиды и мутация flaviviridae |
| WO2011035250A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
| ES2524356T3 (es) | 2010-07-22 | 2014-12-05 | Gilead Sciences, Inc. | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物 |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| EP2852604B1 (en) * | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| AP3913A (en) | 2012-05-22 | 2016-11-26 | Idenix Pharamaceuticals Inc | D-amino acid compounds for liver disease |
| HUE029038T2 (en) | 2012-05-25 | 2017-01-30 | Janssen Sciences Ireland Uc | Uracil spirooxetan nucleosides |
| US9556216B2 (en) | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
| WO2014052638A1 (en) * | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| SG11201502750UA (en) | 2012-10-08 | 2015-06-29 | Idenix Pharmaceuticals Inc | 2'-chloro nucleoside analogs for hcv infection |
| EP2935304A1 (en) * | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| EP2981542B1 (en) * | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| BR112015025766A2 (pt) | 2013-04-12 | 2017-10-17 | Achillion Pharmaceuticals Inc | derivado de nucleosídeo altamente ativo para o tratamento de hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| JP6562908B2 (ja) * | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| WO2015061683A1 (en) * | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| TWI740546B (zh) * | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| GEP20217282B (en) | 2015-03-06 | 2021-08-10 | Atea Pharmaceuticals Inc | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| MX2018002707A (es) * | 2015-09-02 | 2018-08-01 | Abbvie Inc | Derivados de tetrahidrofurano antivirales. |
| HRP20220355T1 (hr) | 2015-09-16 | 2022-05-13 | Gilead Sciences, Inc. | Postupci za liječenje infekcija coronaviridae |
| US11963972B2 (en) | 2016-03-23 | 2024-04-23 | Emory University | Antiviral agents and nucleoside analogs for treatment of Zika virus |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| CA3046504A1 (en) * | 2016-12-15 | 2018-06-21 | Meharry Medical College | Antiviral agents |
| CN110248951B (zh) | 2017-02-01 | 2022-10-28 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| CN116036112A (zh) | 2017-03-14 | 2023-05-02 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| WO2018204198A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| US20210353660A1 (en) * | 2018-10-04 | 2021-11-18 | Octagon Therapeutics Inc. | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs |
| US12419902B2 (en) | 2019-03-31 | 2025-09-23 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN118994170A (zh) | 2020-03-12 | 2024-11-22 | 吉利德科学公司 | 制备1'-氰基核苷的方法 |
| CN111548384B (zh) * | 2020-03-29 | 2021-04-27 | 常州安蒂卫生物科技有限公司 | 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药 |
| EP4132651B1 (en) | 2020-04-06 | 2026-03-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| US10988503B1 (en) * | 2020-05-06 | 2021-04-27 | Nantong Weishun Biotechnology Co., Ltd | Six-membered ring-containing nucleoside compound and preparation method thereof |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| CA3187821A1 (en) | 2020-06-24 | 2021-12-30 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| WO2022038539A2 (en) | 2020-08-18 | 2022-02-24 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
| WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| KR20240006536A (ko) * | 2021-04-09 | 2024-01-15 | 에모리 유니버시티 | 항바이러스제로서의 티오뉴클레오시드 |
| JP7688152B2 (ja) | 2021-04-16 | 2025-06-03 | ギリアード サイエンシーズ， インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
| JP7719954B2 (ja) | 2021-08-18 | 2025-08-06 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物並びにその製造方法及び使用方法 |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| EP4493573A1 (en) | 2022-03-15 | 2025-01-22 | Rome Therapeutics, Inc. | Compounds and methods for treating disease |
| WO2024016639A1 (zh) * | 2022-07-21 | 2024-01-25 | 华创合成制药股份有限公司 | 一种抗病毒感染的化合物及其制备方法和用途 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024169774A2 (en) * | 2023-02-17 | 2024-08-22 | Ascletis BioScience Co., Ltd | Nucleoside and nucleotide analogs, methods of making and methods of use thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| NO171507C (no) | 1988-11-21 | 1993-03-24 | Syntex Inc | Analogifremgangsmaate ved fremstilling av terapeutisk aktive nukleotidderivater |
| AU651835B2 (en) | 1990-06-13 | 1994-08-04 | Arnold Glazier | Phosphorous prodrugs |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| AU1262001A (en) | 1999-11-04 | 2001-05-14 | Biochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| CN1427722A (zh) | 2000-02-18 | 2003-07-02 | 希拉生物化学股份有限公司 | 用核苷类似物治疗或预防黄病毒感染的方法 |
| PY0111577A (es) | 2000-05-23 | 2017-01-02 | Idenix Cayman Ltd | Métodos y composiciones para el tratamiento del virus de la hepatitis c |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| JP2004533406A (ja) | 2000-10-18 | 2004-11-04 | フアーマセツト・リミテツド | ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド |
| CN1137132C (zh) * | 2000-12-14 | 2004-02-04 | 华东理工大学 | 一种氰基呋喃核苷化合物及其制备方法 |
| AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| SI1355916T1 (sl) | 2001-01-22 | 2007-04-30 | Merck & Co Inc | Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze |
| EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
| US7321033B2 (en) * | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
| PT1523489E (pt) | 2002-06-28 | 2014-06-24 | Centre Nat Rech Scient | Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae |
| RU2005118421A (ru) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-разветвленные нуклеозиды и мутация flaviviridae |
| AU2003292772A1 (en) * | 2002-12-26 | 2004-07-22 | Nippon Shinyaku Co., Ltd. | PROCESS FOR PRODUCING PNPase |
| BRPI0419345B8 (pt) | 2003-05-30 | 2021-05-25 | Gilead Pharmasset Llc | uso do (2r)-2-desoxi-2-flúor-2-c-metil nucleosídeo e de uma composição farmacêutica que o compreende |
| PE20050249A1 (es) | 2003-07-25 | 2005-06-01 | Aventis Pharma Gmbh | Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos |
| PT1773856E (pt) | 2004-07-21 | 2012-05-14 | Gilead Pharmasset Llc | Preparação de 2-desoxi-2-fluoro-d-ribofuranosilo pirimidinas e purinas substituídas com alquilo e seus derivados |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| US7951789B2 (en) * | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| SI2114980T1 (sl) | 2007-01-12 | 2012-11-30 | Biocryst Pharm Inc | Protivirusni nukleozidni analogi |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| AU2008251555B2 (en) | 2007-05-10 | 2012-08-30 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer |
| GB0709791D0 (en) | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
| JO3027B1 (ar) * | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
-
2012
- 2012-04-13 ES ES12716969T patent/ES2744587T3/es active Active
- 2012-04-13 EA EA201391264A patent/EA201391264A1/ru unknown
- 2012-04-13 US US13/447,017 patent/US8877733B2/en active Active
- 2012-04-13 MX MX2013011915A patent/MX2013011915A/es not_active Application Discontinuation
- 2012-04-13 CN CN2012800181025A patent/CN103476783A/zh active Pending
- 2012-04-13 WO PCT/US2012/033675 patent/WO2012142523A2/en not_active Ceased
- 2012-04-13 EP EP12716969.6A patent/EP2697241B1/en active Active
- 2012-04-13 JP JP2014505381A patent/JP6043338B2/ja not_active Expired - Fee Related
- 2012-04-13 BR BR112013026219A patent/BR112013026219A2/pt not_active IP Right Cessation
- 2012-04-13 KR KR1020137029678A patent/KR20140019832A/ko not_active Withdrawn
- 2012-04-13 AU AU2012242517A patent/AU2012242517B2/en not_active Ceased
- 2012-04-13 CA CA2830689A patent/CA2830689A1/en not_active Abandoned
-
2013
- 2013-10-02 IL IL228680A patent/IL228680A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518835A5 (enExample) | ||
| JP2012517444A5 (enExample) | ||
| JP2011521903A5 (enExample) | ||
| JP2013538230A5 (enExample) | ||
| ME02656B (me) | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje | |
| HRP20150359T1 (hr) | 1'-supstituirani karba-nukleozidni analozi za antivirusnu terapiju | |
| JP2013514359A5 (enExample) | ||
| JP2010539241A5 (enExample) | ||
| CA2553879A1 (en) | Viral polymerase inhibitors | |
| RU2483073C2 (ru) | Фосфадиазиновые ингибиторы iv полимеразы hcv | |
| JP2011511841A5 (enExample) | ||
| JP2012504132A5 (enExample) | ||
| JP2012512169A5 (enExample) | ||
| JP2012504632A5 (enExample) | ||
| JP2014503516A5 (enExample) | ||
| RU2015123641A (ru) | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний | |
| JP2012504126A5 (enExample) | ||
| JP2012504129A5 (enExample) | ||
| JP2012519691A5 (enExample) | ||
| JP2011520906A5 (enExample) | ||
| JP2015525220A5 (enExample) | ||
| JP2011523651A5 (enExample) | ||
| AR066165A1 (es) | Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridae | |
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| JP2011079828A5 (enExample) |